Internal Neuromodulation Devices Global Market Report 2024

The internal neuromodulation devices market has grown strongly in recent years. It will grow from $2.47 billion in 2023 to $2.66 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The expansion observed in the historical period can be attributed to factors such as the management of chronic pain, the aging population, increased focus on clinical research and trials, the prevalence of neurological disorders, and growing patient awareness and acceptance of internal neuromodulation devices.

The internal neuromodulation devices market is expected to see strong growth in the next few years. It will grow to $3.61 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The anticipated growth in the forecast period can be attributed to trends in personalized medicine, increasing healthcare expenditure, collaborations and partnerships within the industry, a focus on patient outcomes and real-world evidence, and changes in the regulatory landscape. Key trends expected in the forecast period encompass advancements in miniaturization and implantable technology, the integration of wireless connectivity and remote monitoring, expanded applications for neuromodulation, the development of closed-loop systems for precise modulation, and a heightened focus on patient-centric design.

The anticipated increase in the prevalence of neurologic diseases is poised to drive the growth of the internal neuromodulation devices market in the foreseeable future. Neurologic diseases encompass a wide range of disorders affecting the nervous system, including the brain, spinal cord, and peripheral nerves. Internal neuromodulation devices play a crucial role in treating neurological and psychiatric conditions by administering electrical stimulation to specific areas of the nervous system, offering relief from symptoms such as chronic pain, movement disorders, and mood disorders. These devices contribute to enhancing patients' quality of life by alleviating symptoms and facilitating daily activities. For example, in 2021, the Centers for Disease Control and Prevention reported that Alzheimer's disease affected approximately 6.2 million Americans aged 65 and older, a number expected to nearly triple to 14 million by 2060. Additionally, the incidence of the disease doubles every five years after the age of 65. Thus, the increasing prevalence of neurologic diseases is a driving force behind the growth of the internal neuromodulation devices market.

The rising incidence of brain cancers is anticipated to fuel the expansion of the internal neuromodulation devices market. Brain cancer, a diverse group of tumors originating in the brain or spinal cord, poses complex challenges for understanding and treatment. Internal neuromodulation devices emerge as a promising therapeutic solution for various brain disorders, delivering electrical stimulation or other forms of energy directly to specific brain regions to modulate neuronal activity and induce therapeutic effects. In 2022, the National Brain Tumor Society reported an expected diagnosis of brain tumors in approximately 94,390 Americans, with an estimated 18,990 deaths from malignant brain tumors in 2023. Thus, the growing incidence of brain cancers serves as a catalyst for the growth of the internal neuromodulation devices market.

A prominent trend gaining traction in the internal neuromodulation devices market is product innovation. Major companies in this segment are actively engaged in developing new technologies to maintain their market positions. For instance, in March 2023, Ireland-based medical equipment manufacturer Neuromod Device Ltd. announced that its Lenire system had received De Novo clearance from the US Food and Drug Administration (FDA). The Lenire system employs a combination of sound stimulation and tongue stimulation to treat tinnitus, a neurological disorder characterized by ringing in the ears. This innovative system uses a dual-pronged approach to neurostimulation, utilizing Bluetooth headphones to play unique sounds stimulating the auditory nerve, while Neuromod's Tonguetip device transmits moderate electrical stimulation to the tongue's surface. This technology provides otolaryngologists with an innovative tool to recommend to patients experiencing a moderately negative impact on their lives due to tinnitus.

Major companies in the internal neuromodulation devices market are concentrating on developing technological innovations, including digital health apps, to gain a competitive edge. Digital health apps are software applications designed to deliver health-related services and information to users on mobile devices. For example, in July 2022, US-based medical device provider Abbott Laboratories launched the NeuroSphere Virtual Clinic, a groundbreaking technology allowing patients with Abbott's neurostimulation devices to remotely communicate with doctors. This feature enables patients to ensure proper settings, functionality, and receive new treatment settings via secure in-app video chat and integrated remote programming. The platform provides real-time data to physicians about patients' device usage and pain levels.

In March 2022, US-based medical equipment manufacturer Electromedical Products International (EPI) acquired Pulvinar Neuro for an undisclosed amount. Through this acquisition, Pulvinar Neuro gains enhanced capabilities for promoting its patented technologies, such as transcranial alternating current stimulation (tACS). Additionally, the acquisition enhances its cloud-enabled digital treatments for mental and neurological conditions and customized feedback stimulation. Pulvinar Neuro is a US-based medical technology company specializing in deep brain stimulation (DBS) systems for treating neurological and psychiatric disorders.

Major companies operating in the internal neuromodulation devices market report are Medtronic plc, Boston Scientific Corporation, Cyberonics Inc., BioControl Medical Ltd., Aleva Neurotherapeutics SA, Bioness Inc., Uroplasty Inc., Abbott Laboratories, St. Jude Medical Inc., EnteroMedics Inc., Micron Medical Corporation, LivaNova plc, NeuroPace Inc., Synapse Biomedical Inc., Soterix Medical Inc., Accellent Inc., Neuros Medical Inc., Nevro Corp., Nuvectra Corporation, Stimwave Technologies Incorporated, SPR Therapeutics, Axonics Modulation Technologies Inc., Saluda Medical Pty Limited, MicroTransponder Inc., EndoStim Inc., NeuroMetrix Inc., Second Sight Medical Products Inc., Neurotech International Limited, Neuronix Ltd., Neuronoff Inc.

North America was the largest region in the internal neuromodulation devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global internal neuromodulation devices market report during the forecast period. The regions covered in the internal neuromodulation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the internal neuromodulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of internal neuromodulation devices include spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and gastric neurostimulators. These devices utilize different technologies, encompassing both internal and external neuromodulation, along with biomaterials such as metallic biomaterials, polymeric biomaterials, and ceramic biomaterials. They find applications in treating conditions such as failed back surgery syndrome, Parkinson's disease, urinary incontinence, epilepsy, and gastroparesis. The end-users of these devices span hospitals, clinics, home healthcare, and community healthcare.

The internal neuromodulation devices market research report provides internal neuromodulation devices market statistics, including internal neuromodulation devices industry global market size, regional shares, competitors with a internal neuromodulation devices market share, detailed internal neuromodulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the internal neuromodulation devices industry. This internal neuromodulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The internal neuromodulation devices market consists of sales of electrodes, leads, receivers, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.